Your browser doesn't support javascript.
loading
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
Halperin, Daniel M; Liu, Suyu; Dasari, Arvind; Fogelman, David; Bhosale, Priya; Mahvash, Armeen; Estrella, Jeannelyn S; Rubin, Laura; Morani, Ajaykumar C; Knafl, Mark; Overeem, Tim A; Fu, Szu-Chin; Solis, Luisa M; Parra Cuentas, Edwin; Verma, Anuj; Chen, Hong-Lei; Gite, Swati; Subashchandrabose, Priya; Dervin, Shannon; Schulze, Katja; Darbonne, Walter C; Yun, Cindy; Wistuba, Ignacio I; Futreal, P Andrew; Woodman, Scott E; Yao, James C.
Afiliação
  • Halperin DM; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Liu S; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
  • Dasari A; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Fogelman D; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
  • Bhosale P; Department of Radiology, University of Texas MD Anderson Cancer Center, Houston.
  • Mahvash A; Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston.
  • Estrella JS; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Rubin L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
  • Morani AC; Department of Radiology, University of Texas MD Anderson Cancer Center, Houston.
  • Knafl M; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Overeem TA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Fu SC; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Solis LM; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Parra Cuentas E; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Verma A; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Chen HL; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Gite S; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Subashchandrabose P; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Dervin S; Genentech, Inc, South San Francisco, California.
  • Schulze K; Genentech, Inc, South San Francisco, California.
  • Darbonne WC; Genentech, Inc, South San Francisco, California.
  • Yun C; Genentech, Inc, South San Francisco, California.
  • Wistuba II; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Futreal PA; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Woodman SE; Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston.
  • Yao JC; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
JAMA Oncol ; 8(6): 904-909, 2022 06 01.
Article em En | MEDLINE | ID: mdl-35389428
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: JAMA Oncol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: JAMA Oncol Ano de publicação: 2022 Tipo de documento: Article